Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis

John MascarenhasIcahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA; Correspondence[email protected]

Maria R. BaerGreenebaum Cancer Center, University of Maryland, Baltimore, MD, USA; View further author information

Craig KesslerLombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washinton, DC, USA; View further author information

Elizabeth HexnerAbramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA; View further author information

Douglas TremblayIcahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA;

Leah PriceDepartment of Population Health, New York University, New York, NY, USA; View further author information

Lonette SandyIcahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA; View further author information

Rona WeinbergNew York Blood Center, Myeloproliferative Disorders Laboratory, New York, NY, USA; View further author information

Heike PahlSection of Molecular Hematology, Department of Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany; View further author information

Lewis R. SilvermanIcahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA; View further author information

Judith D. GoldbergDepartment of Population Health, New York University, New York, NY, USA; View further author information

Heidi KosiorekDivision of Biostatistics, Mayo Clinic Arizona, Scottsdale, AZ, USAView further author information

Amylou C. DueckDivision of Biostatistics, Mayo Clinic Arizona, Scottsdale, AZ, USAView further author information

Ronald HoffmanIcahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA; View further author information

Your download is now in progress and you may close this window